ADA 2018: CV Benefits of SGLT-2 Inhibitors

Three studies at ADA 2018 highlight the current track record of SGLT-2is in reducing CV-related morbidity and mortality.

Source: ConsultantLive - June 28, 2018 Category: Internal Medicine Authors: Kenneth J. Bender, PharmD, MA Tags: Diabetes Source Type: news